Literature DB >> 17099139

Molecular pathogenesis of lymphangioleiomyomatosis: lessons learned from orphans.

Stephen C Juvet1, Francis X McCormack, David J Kwiatkowski, Gregory P Downey.   

Abstract

Lymphangioleiomyomatosis (LAM) is a rare progressive cystic lung disease affecting young women. The pivotal observation that LAM occurs both spontaneously and as part of the tuberous sclerosis complex (TSC) led to the hypothesis that these disorders share common genetic and pathogenetic mechanisms. In this review we describe the evolution of our understanding of the molecular and cellular basis of LAM and TSC, beginning with the discovery of the TSC1 and TSC2 genes and the demonstration of their involvement in sporadic (non-TSC) LAM. This was followed by rapid delineation of the signaling pathways in Drosophila melanogaster with confirmation in mice and humans. This knowledge served as the foundation for novel therapeutic approaches that are currently being used in human clinical trials.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17099139      PMCID: PMC2176113          DOI: 10.1165/rcmb.2006-0372TR

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  131 in total

1.  Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis.

Authors:  T Carsillo; A Astrinidis; E P Henske
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

2.  Similarities and differences in the subcellular localization of hamartin and tuberin in the kidney.

Authors:  V Murthy; L A Haddad; N Smith; D Pinney; R Tyszkowski; D Brown; V Ramesh
Journal:  Am J Physiol Renal Physiol       Date:  2000-05

3.  Simultaneous loss of hamartin and tuberin from the cerebrum, kidney and heart with tuberous sclerosis.

Authors:  M Mizuguchi; K Ikeda; S Takashima
Journal:  Acta Neuropathol       Date:  2000-05       Impact factor: 17.088

4.  The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho.

Authors:  R F Lamb; C Roy; T J Diefenbach; H V Vinters; M W Johnson; D G Jay; A Hall
Journal:  Nat Cell Biol       Date:  2000-05       Impact factor: 28.824

5.  Downregulation of estrogen and progesterone receptors in the abnormal smooth muscle cells in pulmonary lymphangioleiomyomatosis following therapy. An immunohistochemical study.

Authors:  K Matsui; K Takeda; Z X Yu; J Valencia; W D Travis; J Moss; V J Ferrans
Journal:  Am J Respir Crit Care Med       Date:  2000-03       Impact factor: 21.405

6.  High frequency of pulmonary lymphangioleiomyomatosis in women with tuberous sclerosis complex.

Authors:  L C Costello; T E Hartman; J H Ryu
Journal:  Mayo Clin Proc       Date:  2000-06       Impact factor: 7.616

Review 7.  Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent.

Authors:  D B Mendel; A D Laird; B D Smolich; R A Blake; C Liang; A L Hannah; R M Shaheen; L M Ellis; S Weitman; L K Shawver; J M Cherrington
Journal:  Anticancer Drug Des       Date:  2000-02

8.  Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM).

Authors:  Elena A Goncharova; Dmitry A Goncharov; Andrew Eszterhas; Deborah S Hunter; Marilyn K Glassberg; Raymond S Yeung; Cheryl L Walker; Daniel Noonan; David J Kwiatkowski; Margaret M Chou; Reynold A Panettieri; Vera P Krymskaya
Journal:  J Biol Chem       Date:  2002-06-03       Impact factor: 5.157

9.  TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling.

Authors:  Ken Inoki; Yong Li; Tianquan Zhu; Jun Wu; Kun-Liang Guan
Journal:  Nat Cell Biol       Date:  2002-09       Impact factor: 28.824

10.  Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway.

Authors:  Brendan D Manning; Andrew R Tee; M Nicole Logsdon; John Blenis; Lewis C Cantley
Journal:  Mol Cell       Date:  2002-07       Impact factor: 17.970

View more
  34 in total

Review 1.  Current views on the function of the lymphatic vasculature in health and disease.

Authors:  Yingdi Wang; Guillermo Oliver
Journal:  Genes Dev       Date:  2010-10-01       Impact factor: 11.361

2.  Differential IKK/NF-κB Activity Is Mediated by TSC2 through mTORC1 in PTEN-Null Prostate Cancer and Tuberous Sclerosis Complex Tumor Cells.

Authors:  Yu Gao; Ronald B Gartenhaus; Rena G Lapidus; Arif Hussain; Yanting Zhang; Xinghuan Wang; Han C Dan
Journal:  Mol Cancer Res       Date:  2015-09-15       Impact factor: 5.852

3.  Diagnostic potential of serum VEGF-D for lymphangioleiomyomatosis.

Authors:  Lisa R Young; Yoshikazu Inoue; Francis X McCormack
Journal:  N Engl J Med       Date:  2008-01-10       Impact factor: 91.245

4.  Treatment option(s) for pulmonary lymphangioleiomyomatosis: progress and current challenges.

Authors:  Vera P Krymskaya
Journal:  Am J Respir Cell Mol Biol       Date:  2012-05       Impact factor: 6.914

Review 5.  Lymphangioleiomyomatosis: A Monogenic Model of Malignancy.

Authors:  Vera P Krymskaya; Francis X McCormack
Journal:  Annu Rev Med       Date:  2017-01-14       Impact factor: 13.739

6.  TSC2 modulates cell adhesion and migration via integrin-α1β1.

Authors:  Lyn M Moir; Judith L Black; Vera P Krymskaya
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-08-24       Impact factor: 5.464

7.  Lymphangioleiomyomatosis: current and future.

Authors:  Maria Mavroudi; Paul Zarogoulidis; Nikolaos Katsikogiannis; Kosmas Tsakiridis; Haidong Huang; Antonios Sakkas; Anastasios Kallianos; Aggeliki Rapti; Eirini Sarika; Ilias Karapantzos; Konstantinos Zarogoulidis
Journal:  J Thorac Dis       Date:  2013-02       Impact factor: 2.895

8.  Prevention of alveolar destruction and airspace enlargement in a mouse model of pulmonary lymphangioleiomyomatosis (LAM).

Authors:  Elena A Goncharova; Dmitry A Goncharov; Melane Fehrenbach; Irene Khavin; Blerina Ducka; Okio Hino; Thomas V Colby; Mervyn J Merrilees; Angela Haczku; Steven M Albelda; Vera P Krymskaya
Journal:  Sci Transl Med       Date:  2012-10-03       Impact factor: 17.956

9.  Predictors for clinical trial participation in the rare lung disease lymphangioleiomyomatosis.

Authors:  Brent W Kinder; A C Sherman; L R Young; J T Hagaman; N Oprescu; S Byrnes; Francis X McCormack
Journal:  Respir Med       Date:  2009-12-04       Impact factor: 3.415

10.  Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors.

Authors:  Chelsey Woodrum; Alison Nobil; Sandra L Dabora
Journal:  J Transl Med       Date:  2010-02-10       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.